Patientportal.aegislabs.com – Aegis COVID-19 Testing Portal

Aegis TAT is calculated from the moment samples are entered into our tracking system for laboratory tests from the moment they are logged into our laboratory tracking system until test reports are made public. It doesn’t include the the time it takes to get lab results. Aegis collaborates with all their collection partners in order to make the utilization of overnight shipping to its lab following the collection. The delay in shipping and the scheduling of shipping on weekends could affect the amount of time between the time of the collection until the end of Aegis report.

Please continue to check the patient portal for the latest updates: patientportal.aegislabs.com.

Once the sample has been received by lab and testing is in progress When the test is in progress, the portal will indicate that the sample was received and that testing is currently in progress. The results will be posted on the portal when testing is completed. You will be notified via email of the results as soon as you’ve received your test results are made public.

Through the last calendar year, more than a million people across the globe are suffering from illnesses caused by the transmission of SARS-CoV-2. Despite the rapid growth of information about the virus responsible for COVID-19 healthcare providers and epidemiologists, virologists and laboratory scientists have frequently been fighting a tough fight to stop the spread of COVID-19 and in treating patients suffering from COVID-19.

In the past couple of months, we’ve discovered that the SARS-CoV-2 virus as well as other respiratory pathogens it, has gone through a changes that could lead to an increased risk of infection and disease. Variants of this virus that are genetic, such as B.1.1.7 as well as 501Y.V2 have attracted the interest from the general public as well as people who assist in treating COVID-19 because of their increased in transmission. There have also been questions about the effectiveness of widely used testing methods to recognize the new genetic variants.

Aegis Sciences Corporation uses The Thermo Fisher Scientific TaqPath(tm) COVID-19 Combo Kit to perform COVID-19 Diagnostic testing. This extremely sensitive and precise testing method examines 3 genetic markers that are exclusive to SARS-CoV-2.

The FDA has acknowledged that its sensitivity or potential of false negative results in the TaqPath(tm) COVID-19 Combo Kit isn’t expected to be affected by the current COVID versions (i.e. B.1.17). The FDA’s comment is supported by recent findings which show that because of the targeted targeting of three genes during testing and this TaqPath kit was proven not to produce false negative results based on testing of people infected by COVID different strains. ^1,2It is possible that other testing methods that don’t utilize 3 gene targets could be affected by these new variant strains. Also read Brenda Gantt cookbook – It’s Gonna Be Good Y’all

Aegis Sciences Corporation will continue to supply healthcare providers with sensitive and precise diagnostic test results with an acceptable turnaround time for clinically relevant tests which has been achieved this by performing more than 3 million tests. Our lab and clinical scientists will continue to study the literature in the field and make clinical guidelines for testing in the midst of ongoing changes through the Pandemic.

Our goal is to assist clinicians make better decisions , and we’ll keep doing this by providing rapid, accurate and technically top-quality performance.